Harvoni is the new tablet launched this month by Gilead Sciences, Inc (NASDAQ GILD) which Stewart acquired first because she take part in its clinical trials. Harvoni is a mixture of the novel drug ledipasvir and sofosbuvir, which for closely a year has been sold only under the brand name Sovaldi.

Sovaldi’s launch shattered all earlier new drug launches. Since it came out in December 2013 it has plagued up almost $6B in sales and that’s earlier Gilead’s third quarter report, which is declare on Oct. 28. Since Harvoni is the new and developed Sovaldi, analysts anticipate it to treat even other patients.

Bristol-Myers Squibb Co (NYSE BMY) declared well than expected Q3 results as hot sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes referring the stock up 2.6%. The U.S. drug manufacturer declared on Friday that it earned $721M or 43 cents per share in the quarter versus $692M, or 42 cents per share, in the similar period a year ago.

Biotech Stock News

Without special items, Bristol-Myers Squibb Co (NYSE BMY) earned 45 cents per share; surpass the average expert estimate of 42 cents per share, according to a surveyed by Thomson Reuters. The effective tax rate was 27.4% compared with 15.4% in previous year. Sanford Bernstein expert Tim Anderson, who projected a 13% tax rate, saw some other material updates on its finances or products in the earnings report.

A clinical-stage biopharmaceutical firm focused on the discovery, growth and commercialization of recombinant nanoparticle vaccines and adjuvants, Novavax, Inc (NASDAQ NVAX) declared that Gregory Glenn, M.D., SVP, R&D is presenting innovative immunogenicity data from Novavax’ RSV F-Protein Nanoparticle vaccine applicant clinical trials at the 8th Vaccine & ISV Congress in Philadelphia, PA.

Biotech Financial News

Insmed (INSM) targets the development of lung disease treatments utilizing inhalation therapies. The company’s lead drug candidate is dubbed ARIKACE and attacks the lung infections, including those suffering from cystic fibrosis. The market opportunity is ripe for INSM stock since there are currency no inhalation-based antibiotics available.

Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.